BIOMAT Database Logo BIOMAT Database Logo

[Personal experience in the treatment of chronic viral hepatitis B with recombinant interferon B alfa-2]. 1994

D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
Vojnomedicinska akademija, Institut za patologiju i sudsku medicinu, Beograd.

Twelve patients were treated with alpha-2 recombinant interferon during 4 months. Patients were given daily dose of 3 million units three times a week. Therapeutic effect expressed as the percentage of HBeAG seroconversion or by the loss of antibodies for the core antigen in IgM fraction and by the core antigen loss from hepatic tissue, was achieved in 41.6% of patients. Corticosteroids, administered before interferon, could improve therapeutic effect. Better response to therapy was observed in patients with higher serum transaminase levels and with histopathologically confirmed chronic hepatitis. Predictive value of each immunological parameter of therapeutic effect requires further study.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
[Treatment of chronic viral hepatitis with recombinant interferon-alfa].
July 1992, Orvosi hetilap,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
[Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant alfa-2 interferon].
January 2000, Vojnosanitetski pregled,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
[The efficacy of recombinant alfa-2 interferon in viral hepatitis B].
September 1990, Vrachebnoe delo,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
[Treatment of chronic viral hepatitis B with interferon alfa. Experience of the last 3 years].
February 1996, Casopis lekaru ceskych,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
[The use of recombinant alfa-2 interferon in treating patients with acute and chronic viral hepatitis B].
January 1998, Likars'ka sprava,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
[Recombinant alfa-2 interferon treatment of a patient with chronic hepatitis B and ulcerative colitis].
February 1996, Gastroenterologia y hepatologia,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
Interferon alfa in the treatment of chronic viral hepatitis B and C.
March 1997, The Annals of pharmacotherapy,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
Treatment of chronic hepatitis C with recombinant interferon alfa.
January 1991, The Italian journal of gastroenterology,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
Treatment of chronic hepatitis C with recombinant interferon alfa.
January 1992, The Western journal of medicine,
D Nozić, and P Mijusković, and I Bojić, and V Marinković, and J Dimitrijević, and N Milosević, and N Kuljić-Kapulica, and M Dokić, and N Dordević
Treatment of chronic hepatitis C with recombinant interferon alfa-2b.
January 1993, Gut,
Copied contents to your clipboard!